Canon's CT portfolio primed for lung cancer screening

Canon Medical Systems said the majority of its CT scanners and software have...Read more on AuntMinnie.comRelated Reading: Canon installs 3T MRI scanner in Colo. Canon makes 1st Alphenix Core+ install in Fla. Canon launches Encore Orian MR upgrade program Canon delivers 1st Alphenix 4D CT to W.Va. hospital Canon gets FDA nod for AI-powered CT reconstruction
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Canon Medical Systems USA has introduced Alphenix Aero Edition, a new interventional...Read more on AuntMinnie.comRelated Reading: Canon plans to open Middle East division Canon unveils Alphenix Encore Plus Program Canon's CT portfolio primed for lung cancer screening Canon installs 3T MRI scanner in Colo. Canon makes 1st Alphenix Core+ install in Fla.
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
ng Wenyi Kang Two novel water soluble heteroglycan (PCp-I and PCp-II) with anti-A549 lung cancer cells activity were isolated from Psoralea corylifolia L. Their average molecular weights were 2.721 × 104 and 2.850 × 104. PCp-I and PCp-II had the same monosaccharide composition, but their molar ratios were different. Based on methylation and NMR spectroscopy, the part structure of PCp-I was identified. The results of scanning electron microscope (SEM) showed that PCp-I had an irregular porous structure and PCp-II was flaky and irregularly curved. The results of thermogravimetry-differential scannin...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Canon Medical Systems is preparing to open its Middle East division in Dubai,...Read more on AuntMinnie.comRelated Reading: Canon unveils Alphenix Encore Plus Program Canon's CT portfolio primed for lung cancer screening Canon installs 3T MRI scanner in Colo. Canon makes 1st Alphenix Core+ install in Fla. Canon launches Encore Orian MR upgrade program
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
In conclusion, tumor imaging phenotypes that are driven by somatic mutations may be predicted by radiomics based on PET/CT images.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
AbstractObjectiveMetabolic tumor volume (MTV) and total lesion glycolysis (TLG) are imaging parameters derived from 18F-FDG PET/CT that have been proposed for risk stratification of cancer patients. The aim of our study was to test whether these whole-body volumetric imaging parameters may predict outcome in patients with non-small cell lung cancer (NSCLC).MethodsSixty-five patients (45 men, 20 women; mean age  ± SD, 65 ± 12 years), with histologically proven NSCLC who had undergone 18F-FDG PET/CT scan before any therapy, were included in the study. Imaging parameters includin...
Source: Annals of Nuclear Medicine - Category: Nuclear Medicine Source Type: research
Canon Medical Systems USA has introduced its Alphenix Encore Plus Program,...Read more on AuntMinnie.comRelated Reading: Canon's CT portfolio primed for lung cancer screening Canon installs 3T MRI scanner in Colo. Canon makes 1st Alphenix Core+ install in Fla. Canon launches Encore Orian MR upgrade program Canon delivers 1st Alphenix 4D CT to W.Va. hospital
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Results from a phase III clinical trial comparing Keytruda (pembrolizumab) to standard chemotherapy shows the immunotherapy drug still has a long way to go as a viable treatment option for malignant pleural mesothelioma. Keytruda did not improve progression-free survival for mesothelioma patients who progressed after first-line chemotherapy. The disappointing results from the PROMISE-meso study were presented at the European Society of Medical Oncology (ESMO) annual meeting last week. It was the first randomized trial comparing progression-free survival between immunotherapy and first-line chemotherapy for mesothelioma p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
AbstractThere is little consensus in the literature about the administration of crizotinib in patients with end ‐stage renal disease undergoing hemodialysis. A 69‐year‐old male patient, who was receiving regular hemodialysis due to end‐stage renal disease, visited the hospital with symptoms of repeated abdominal pain. There was no suspicious finding of cancer within the thorax. After biopsy, the abdom inal lymph nodes were identified as adenocarcinoma originating from the lung following computed tomography (CT) scan, and ALK rearrangement was confirmed. The patient achieved a partial response following the administ...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
ConclusionsQuantifying CT density change within irradiated lung parenchyma may offer a novel approach to predict radiation associated pulmonary toxicities. Measuring density changes across patient cohorts receiving TRT with novel systemic therapies may help to identify combined treatment strategies likely to be associated with diminished risk of toxicity.Legal entity responsible for the studyThe authors.FundingBristol-Myers Squibb.DisclosureS. Kim: Research grant / Funding (institution): Bristol-Myers Squibb. S.A. Rosenberg: Advisory / Consultancy: Novocure. J.E. Gray: Honoraria (self), Advisory / Consultancy, Research gra...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this analysis, nivo was not associated with HP in the pbo-controlled CheckMate 451 trial. These data are consistent with the previous analysis of ATTRACTION-2, suggesting that reports of HP with immunotherapy may reflect some patients ’ natural course of disease.Clinical trial identificationCheckMate 451 trial: NCT02538666.ONO-4538-12/ATTRACTION-2 trial: NCT02267343.Editorial acknowledgementStephen Gutkin and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb.Legal entity responsible for the studyBristol-Myers Squibb and ONO Pharmaceutical Co. Ltd.FundingBristol-Myers Squibb and ONO Phar...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | Lung Cancer | PET Scan | Radiology